A drug already on the market has been shown to reduce brain damage after strokes in patients with type 2 diabetes. Currently, the only available treatment to decrease the consequences of a stroke is thrombolysis, a chemical that dissolves blood clots in vessels of the brain when quickly administered.
However, as Science Codex reports, linagliptin, which has been used comercially as an antidiabetic drug, is able to largely reduce the damage from strokes. Thrombolysis is only available for 10 percent of stroke victims, so researchers are hoping these new findings will open linagliptin to a larger group of patients, even without diabetes.
The rest of their findings are in the latest issue of the scientific journal Diabetes.